Kinrix is a combination vaccine that protects children against four diseases in a single shot: diphtheria, tetanus, pertussis (whooping cough), and polio. It’s approved for children ages 4 through 6 and serves as the fifth and final dose in the DTaP series and the fourth dose in the polio vaccine series. The FDA licensed Kinrix in June 2008, and it’s manufactured by GlaxoSmithKline Biologicals.
What Kinrix Protects Against
Each of the four diseases Kinrix targets poses a serious risk to young children. Diphtheria causes a thick coating in the back of the throat that can lead to breathing problems and heart failure. Tetanus, sometimes called lockjaw, causes painful muscle stiffening throughout the body and enters through cuts or wounds. Pertussis spreads easily and triggers violent coughing fits that can last for weeks, making it especially dangerous for very young children. Polio can attack the nervous system and cause permanent paralysis.
By combining protection against all four into one injection, Kinrix reduces the total number of shots a child needs at their pre-kindergarten checkup.
Who Should Get It
Kinrix is specifically approved for children aged 4 through 6 (before their seventh birthday). It’s not used for the earlier doses in the vaccine series. Your child will have already received four DTaP shots and three polio shots during infancy and toddlerhood before Kinrix comes into play. This single dose covers both the fifth DTaP and fourth polio booster at once.
Children who had a severe allergic reaction to a previous dose of any diphtheria, tetanus, pertussis, or polio vaccine should not receive Kinrix. The same applies to children who experienced a brain-related complication (encephalopathy) within seven days of a prior pertussis-containing vaccine that had no other identifiable cause.
Common Side Effects
Clinical trials involving thousands of children found that Kinrix’s side effects are similar to what you’d see with separate DTaP and polio shots. The most common reaction is pain at the injection site, reported in about 57% of children. Redness at the injection site occurred in roughly 37%, and swelling in about 26%. Around 36% of children had a temporary increase in arm circumference near where the shot was given.
Whole-body reactions were less common. About 19% of children experienced some drowsiness, 16% had a reduced appetite, and 6.5% developed a low-grade fever. These side effects typically appeared within the first four days and resolved on their own. The rates were nearly identical to those seen in children who received separate DTaP and polio vaccines at the same visit, meaning the combination doesn’t add extra risk.
How It Works
Kinrix contains inactivated (killed) versions of the pathogens it targets. The diphtheria and tetanus components are toxoids, meaning they use deactivated toxins produced by those bacteria. The pertussis component is acellular, using only specific proteins from the whooping cough bacterium rather than the whole cell. The polio component uses inactivated poliovirus. None of these components can cause the diseases they protect against.
When the vaccine is injected into muscle tissue, the immune system recognizes these harmless fragments as foreign and builds antibodies against them. Because your child has already received earlier doses in infancy, this booster shot strengthens and extends the immune memory built up over those previous rounds of vaccination.
How Kinrix Compares to Similar Vaccines
Kinrix isn’t the only combination vaccine on the childhood schedule. Understanding which vaccines cover which doses helps clarify where each one fits.
- Quadracel covers the same four diseases and is also approved only for the fifth DTaP dose in children ages 4 through 6. It’s essentially an alternative to Kinrix at the same appointment.
- Pediarix combines DTaP with polio and hepatitis B but is used only for the first three doses, in children 6 weeks through 4 years old.
- Pentacel covers DTaP, polio, and Hib disease and is approved for the first four doses in children 6 weeks through 4 years.
- Infanrix and Daptacel are standalone DTaP vaccines (no polio component) that can be used for all five doses from 6 weeks through 6 years.
So while several combination vaccines handle the early doses, Kinrix and Quadracel are the two options designed specifically for that final pre-kindergarten booster. Your child’s pediatrician will choose between them based on availability and which brands were used for the earlier doses, though the vaccines are generally interchangeable within the DTaP series.
What the Appointment Looks Like
Kinrix is given as a single intramuscular injection, typically in the upper arm. The entire process takes seconds. Because this shot is usually given at the 4-to-6-year-old well-child visit, it may be administered alongside other vaccines scheduled for that age, such as MMR and varicella boosters.
Most children experience mild soreness at the injection site for a day or two. A cool compress and normal activity usually help. If your child develops drowsiness or a slight fever, these typically pass within 24 to 48 hours.